ECT Device Reclassification Draft Guidance – Moira Dolan MD to the FDA, 2016
Moira Dolan MD to the FDA regarding ECT draft guidance for the 2016 electroshock device risk reclassifacation.
0 Comments
September 18, 2022
Moira Dolan MD to the FDA regarding ECT draft guidance for the 2016 electroshock device risk reclassifacation.
Many experience vision problems after ECT. This case report shows one way that vision can change dramatically from electroconvulsive therapy.
A response to yet another defence of ECT in the absence of robust efficacy and safety evidence by Professor John Read
Vision disturbance is an ECT side effect few know about. Learn about this serious adverse event and what treatments are available.
An easy to understand explanation of how electricity impacts the brain and bodies of electroconvulsive therapy (ECT) recipients.